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Abstract
We report a biomarker-based non-endoscopic method for detecting Barrett’s esophagus (BE), 
based on detecting methylated DNAs retrieved via a swallowable balloon-based esophageal 
sampling device. BE is the precursor of, and a major recognized risk factor for, developing 
esophageal adenocarcinoma (EAC). Endoscopy, the current standard for BE detection, is not cost-
effective for population screening. We performed genome-wide screening to ascertain regions 
targeted for recurrent aberrant cytosine methylation in BE, identifying high-frequency methylation 
within the CCNA1 locus. We tested CCNA1 DNA methylation as a BE biomarker in cytology 
brushings of the distal esophagus from 173 individuals with or without BE. CCNA1 DNA 
methylation demonstrated an area under the curve (AUC)=0.95 for discriminating BE-related 
metaplasia and neoplasia cases versus normal individuals, performing identically to methylation of 
VIM DNA, an established BE biomarker. When combined, the resulting two biomarker panel was 
95% sensitive and 91% specific. These results were replicated in an independent validation cohort 
of 149 individuals, who were assayed using the same cutoff values for test positivity established in 
the training population. To progress toward non-endoscopic esophageal screening, we engineered 
a well-tolerated, swallowable, encapsulated balloon device able to selectively sample the distal 
esophagus within 5 minutes. In balloon samples from 86 individuals, tests of CCNA1 plus VIM 
DNA methylation detected BE metaplasia with 90.3% sensitivity and 91.7% specificity. 
Combining the balloon sampling device with molecular assays of CCNA1 plus VIM DNA 
methylation enables an efficient, well-tolerated, sensitive, and specific method of screening at-risk 
populations for BE.
Introduction
The incidence of esophageal adenocarcinoma (EAC) has more than quadrupled in the past 
thirty years (1–4), and the prognosis for EAC patients remains poor, with a less than 20% 
survival at 5 years (4, 5). Barrett’s esophagus (BE), a pre-malignant intestinal-type columnar 
metaplasia that replaces the normal squamous mucosa of the distal esophagus, is the only 
known precursor for EAC, but its detection currently requires performing 
esophagogastroduodenoscopy (EGD). Due to the high cost of EGD and the lack of a 
randomized controlled trial demonstrating cost-effective reduction in EAC, endoscopy 
screening for BE has not been routinely recommended (6, 7). Thus, in approximately 95% of 
cases of EAC, the presence of the antecedent BE remains undetected and unknown (8). 
Hence, there is a need for additional methods for BE detection that are less expensive than 
Moinova et al. Page 2
Sci Transl Med. Author manuscript; available in PMC 2018 January 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
EGD and can be widely and readily implemented in an at-risk population. Molecular 
biomarkers for detecting BE are potentially valuable in this regard.
Acquisition of aberrant cytosine methylation within CpG-rich genomic islands is a common 
accompaniment of many cancers and can serve as a neoplasia biomarker (9–13). We have 
previously reported that de novo DNA methylation of the CpG island overlapping the first 
exon of the vimentin gene (mVIM) is a highly sensitive BE biomarker that is present in 
biopsies of approximately 90% of BE patients, suggesting utility of mVIM as a potential 
biomarker for BE screening (14). In an initial pilot study, we further found that mVIM could 
be detected in esophageal brushings, suggesting that mVIM can serve as a molecular 
cytology biomarker to enable non-endoscopic detection of BE (14). Reduced Representation 
Bisulfite Sequencing (RRBS) is a whole-genome approach that allows for unbiased 
assessment of DNA methylation within CpG-dense regions of the human genome, which 
encompass the majority of promoters and other regulatory regions (15, 16). RRBS thus 
provides the potential to identify an extended biomarker panel with increased effectiveness 
for detecting BE.
The aims of this study were hence to identify methylated DNA biomarkers of esophageal 
neoplasia, to define the sensitivity and specificity of such markers in comparison to and/or in 
combination with mVIM for detecting BE metaplasias and related neoplasias, and to further 
test the efficacy of these biomarkers for detecting BE in samples obtained via a non-
endoscopic swallowable balloon-based esophageal sampling device as compared to samples 
obtained via endoscopy directed brushings.
Results
RRBS discovery of DNA methylation biomarkers of esophageal neoplasia
We performed RRBS analysis on a set of 26 esophageal cancer (EAC) biopsies and their 
respective matched normal squamous biopsies, 15 biopsy or brushing samples of Barrett’s 
esophagus (BE), and 5 esophageal cancer cell lines (fig. S1). Out of 3,091,193 analyzable 
CpGs, 26,601 CpGs showed methylation below 10% in all the informative normal squamous 
samples (requiring at least 4 informative normal samples, each having sequencing depth of 
at least 20X). When compared in BE, 1,970 of these CpGs showed > 30% methylation in at 
least 4 samples comprising 45% or more of informative cases (all having sequencing depth 
of >10X). Of these 1,970 CpGs methylated in BE, 1011 CpGs additionally demonstrated 
>30% methylation in at least 8 informative EAC biopsies (all having sequencing depth of 
>10X).
These 1011 CpGs that were differentially methylated between normal squamous versus BE 
and EAC samples were clustered into 412 differentially methylated CpG patches, defined as 
clusters of differentially methylated CpGs each less than 200 bp apart. The best 26 of these 
patches were selected for further inspection (table S1). Of these, the best candidate for 
discriminating BE-related lesions from normal esophagus was a patch of 7 CpGs located on 
chromosome 13, in the CpG island spanning the promoter and 5’ UTR of CCNA1 (Fig. 1A). 
70% of the BEs characterized by RRBS showed average methylation exceeding 30% across 
this patch (Fig. 1B). Moreover, all three informative esophageal cancer cell lines showed 
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nearly 100% methylation across this patch, suggesting that both CCNA1 alleles were 
densely methylated, and that the methylation signal in the biopsies was derived from the 
abnormal Barrett’s epithelial cells (Fig. 1B).
CCNA1 and VIM DNA methylation in esophageal biopsies
To further interrogate the CCNA1-associated DNA methylation patch, we designed a next-
generation sequencing (NGS)-based assay for targeted resequencing of this differentially-
methylated region (Fig. 1A). We targeted a cluster of 21 consecutive CpG residues that 
overlap with the methylated patch identified by RRBS (Fig. 1A). The NGS approach allows 
for determining the methylation status for each of these 21 CpGs across a single individual 
DNA read, and thereby calculating the percent of CpG methylation present across this 
region for each individual CCNA1 locus DNA molecule, thus enabling each DNA read to be 
classified as “methylated” versus “unmethylated”. This approach further provides a metric 
of tissue methylation, corresponding to the percent of all the individual CCNA1 DNA 
molecules identified as methylated (percent of CCNA1 “methylated reads”), that can further 
be referenced as exceeding or not exceeding the upper limit of the normal range. This patch-
based algorithm suppresses background from random methylation of individual CpGs and 
provides enhanced discrimination of normal versus diseased tissue (fig. S2).
We used this method to characterize an expanded set of esophageal biopsies (fig. S1) and to 
compare the performance of DNA methylation at the CCNA1 versus VIM loci, reflecting 
our previous identification of VIM region methylation as a high-performance biomarker of 
esophageal neoplasia (14). CCNA1 locus methylation (mCCNA1) was significantly 
increased in all BE-related lesions versus normal (P<0.001, Fig. 2A), with mCCNA1 
detected in 81% percent of nondysplastic BE, 68% percent of BE with high-grade dysplasia, 
and 90% percent of EAC, but in only 1% of normal squamous samples (classifying a tissue 
as methylated if it had >10% of methylated CCNA1 reads, and classifying a CCNA1 read as 
methylated when methylation was detected at ≥ 16 out of target 21 target CpG positions). 
These results were similar to those obtained by bisulfite-sequencing analysis of these 
samples for VIM locus methylation (mVIM) (Fig. 2B), in which > 10% methylation was 
demonstrated by 100% percent of nondysplastic BE, 63% percent of BE with high-grade 
dysplasia, and 76.5% percent of EAC, but by only 1% of normal squamous samples 
(classifying VIM reads as methylated when methylated at ≥ 8 out of 10 target CpG 
positions).
CCNA1 and VIM DNA methylation for detecting BE and EAC in cytology brushings
To model a “molecular cytology” assay for detecting BE, we used the NGS bisulfite-
sequencing assay to measure CCNA1 DNA methylation (mCCNA1) in a training set of 
esophageal cytology brushings (fig. S1). Brushings of the gastroesophageal (GE) junction 
were obtained from 62 control subjects with or without symptomatic gastroesophageal 
reflux disease (GERD), but without BE. These controls included persons with normal 
endoscopic findings (n=54) plus individuals with erosive esophagitis (n=8). Brushings were 
also obtained from 111 patients including 62 individuals with cancer, either EAC (n=48) or 
GE junction adenocarcinoma (n=14), and 49 individuals with BE. Of BE cases, 12 had non-
dysplastic short-segment BE (SSBE, < 3 cm), 19 had nondysplastic long segment BE (LSBE 
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≥3 cm), 8 had low-grade dysplasia (LGD), and 10 had high-grade dysplasia (HGD). Eighty-
three percent of study participants were white. The disease group was older than controls (P 
< 0.0001) and included more males, reflecting the epidemiology of Barrett’s esophagus. 
There was no significant difference in the prevalence of smoking between cases and controls 
(table S2).
Figure 3A shows the receiver operating characteristic (ROC) curve for mCCNA1 in these 
training set samples, in which the assay demonstrated an area under the curve (AUC) of 
0.95. An optimal cutpoint, in which a sample was detected as positive if it had >3.12% 
methylated CCNA1 templates, maximized the sum of sensitivity plus specificity. At this 
cutpoint, mCCNA1 demonstrated 90.7% sensitivity for detecting BE or cancer with 98.4% 
specificity. As a comparator, Figure 3B shows the ROC curve for the same samples assayed 
for mVIM by bisulfite-sequencing analysis. Similar to mCCNA1, the mVIM assay showed 
an AUC=0.95. The optimal cutpoint for this assay, of 1.05% mVIM content, provided 
sensitivity of 90.7% and specificity of 93.2% (Fig. 3B). These mVIM results are consistent 
with our previous observation in a pilot set of 34 esophageal brushings that were analyzed 
for mVIM by qMS-PCR (14).
To validate the performance of mCCNA1 and mVIM in molecular cytology applications, we 
examined a second independent set of esophageal cytology brushings from 149 new 
individuals recruited at five different cancer centers from across the United States (fig. S1). 
These individuals included 30 controls with normal esophageal morphology and 119 cases 
with BE or cancer (table S2). Similarly to the training set, and reflecting the biology of BE, 
participants in the validation set were 93% white. Training and validation populations did 
not significantly differ by gender or smoking history, but controls were older in the 
validation than in training set (table S2). As shown in Figure 3C and 3D, the validation 
population again showed an AUC of 0.95 for mCCNA1 and 0.96 for mVIM. Moreover, 
sensitivity and specificity of mCCNA1 and mVIM in the validation population replicated 
those of the training population, using the same cutoffs for test positivity as pre-specified by 
the training dataset (Figures 3C, 3D versus 3A, 3B and table S3).
BE progresses from non-dysplastic metaplasias to low and then high grade dysplasias that 
ultimately give rise to EAC (17, 18). Given the equivalent performance of mVIM and 
mCCNA1 in the training and validation populations, we performed a pooled analysis to 
examine these markers’ performance at each of the stages of progression of BE-related 
neoplasias. As shown in Table 1, mCCNA1 and mVIM markers were both highly sensitive 
for detecting each of the stages of BE-related disease, including early non-dysplastic BE 
metaplasias (NDBE), low and the high-grade dysplasias (LGD and HGD), and cancers. 
mVIM performed better than mCCNA1 in detecting non-dysplastic BE (91.5% vs 79.7%), 
whereas mCCNA1 showed a slightly higher sensitivity for dysplastic BE (94.5% vs 91.1%) 
and cancer (94.9% vs 90.7%). When considered in combination, mVIM and mCCNA1 
jointly detected 92% of NDBE, 96% of dysplastic BE, and 96% of cancers, while 
maintaining specificity above 90% for negatively classifying brushings from the normal GE 
junction (Table 1). The combination of mVIM and mCCNA1 was more sensitive than either 
marker individually, even when the specificity of each individual marker was adjusted to 
match that of the combination (table S4).
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Smoking-induced methylation in the upper esophagus
Esophageal brushings under endoscopic guidance provided for directed sampling of the 
distal esophagus. However, certain non-endoscopic approaches to esophageal sampling, for 
example using sponge-based devices, require sampling the entire esophagus. To simulate 
this process, we obtained additional cytology brushings of the proximal normal squamous 
esophagus from all participants in our training population. To avoid contamination, these 
proximal brushings were obtained before any brushings of the GE junction. Unexpectedly, a 
subset of these proximal squamous mucosa brushings tested positive for mVIM or 
mCCNA1, demonstrating methylation values above the cutpoint for normal GE junction as 
determined by the training set of brushings. Positive tests were obtained in 21% of proximal 
squamous samples assayed by mVIM and 6% assayed by CCNA1 (Fig. 4A, 4B). Insight into 
the basis for methylation in the proximal esophagus came from noting that the great majority 
of methylation-positive samples were obtained from current or former smokers, with 
smokers accounting for 75% of samples testing mVIM positive (p=0.0155) and 100% of 
samples testing mCCNA1 positive (p=0.0094). Further review determined that most of the 
methylation-positive normal squamous biopsies from our initial experiments (Fig. 2) also 
came from smokers, though the numbers were too few to support statistical analyses. These 
findings suggest that using methylated DNA markers for non-endoscopic detection of BE 
will be enhanced by device designs that allow for selective sampling of the distal esophagus 
and for protection of samples from contamination by the proximal esophagus.
Reassuringly for such a selective sampling approach, reanalysis of brushings from the distal 
esophagus showed smoking to have no significant effect on the extent of VIM and of 
CCNA1 methylation detectable in either the normal GE junction of control individuals or in 
cases with BE or Barrett’s related neoplasia (table S5).
Detecting BE and EAC via non-endoscopic balloon sampling
To enable non-endoscopic targeted sampling of the distal esophagus, we designed and built 
an encapsulated, inflatable, surface-textured balloon. The device is swallowed in a pill-sized 
16×9 mm capsule attached to a thin 2.16 mm silicone catheter (Fig. 5A, 5B). After delivery 
to the stomach, the balloon is inflated by injecting 5 cc of air through the catheter (Fig. 5C) 
and then gently withdrawn 3 to 6 cm back through the distal esophagus to sample the 
luminal epithelial surface. The balloon is then deflated and inverted back into the capsule 
(Fig. 5D), thus protecting the acquired biosample from further dilution or contamination in 
the proximal esophagus and the oropharynx. After retrieval of the capsule through the 
mouth, DNA is extracted from the balloon surface for molecular analysis.
One hundred fifty six patients underwent unsedated distal esophageal sampling with the 
balloon device before scheduled EGD. The majority of participants were male (71%) and 
white (83%), with an average age of 64.1 (SD = 12.5) years. Twenty-eight (18%) were 
unable to swallow the device. However, the 128 successful participants in trial reported little 
to no anxiety, pain, or choking, and only low to intermediate gagging (table S6). On average, 
the balloon reached the stomach in 3.3 min (range 1.0–7.7 min) with excellent tolerance in 
72% of cases (table S6). Ninety-three percent of individuals who participated in esophageal 
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balloon testing would repeat the procedure again if necessary while 95% would recommend 
it to others (table S6).
From the 128 balloons processed, an adequate DNA amount of at least 60 ng was obtained 
in 116 instances (91%). Thirty individuals were additionally excluded from further analysis 
due to either having a history of prior esophageal ablation for Barrett’s dysplasia (n=23), 
having gastric intestinal metaplasia (n=4), or having intestinal metaplasia (IM) of <1 cm in 
length (ultrashort BE, n=3). The 86 evaluable individuals (table S7) included 36 controls 
free of IM, but with erosive esophagitis (n=3) or other indications for upper endoscopy 
(n=33). The evaluable individuals also included 50 cases, 42 with BE (31 non-dysplastic, 6 
LGD, 4 HGD, 1 indefinite for dysplasia), and 8 with EAC or junctional cancers (Table 2). In 
these balloon samples, mVIM and mCCNA1 discriminated cases and controls with 
performance near identical to that found in the cytology brushing samples, with ROC curves 
for balloon samples demonstrating AUC=0.92 for mCCNA1 and AUC =0.91 for mVIM 
(Fig. 6A versus Fig. 3A, and Fig. 6B versus Fig. 3B). Balloon samples of the normal GE 
junction showed less background methylation of CCNA1 than did cytology brushings, and at 
a cutpoint of 1% for mCCNA1, the assay detected 72% of cases while retaining 100% 
specificity (Table 2). mVIM demonstrated essentially the same cutpoint in balloon samples 
(1%) as in cytology brushings, and the mVIM assay detected 80% of cases with specificity 
of 91.7% (Table 2). When the two markers were jointly applied to the balloon samples, the 
panel detected 90.3% of nondysplastic BE cases with a specificity of 91.7% (Table 2). The 
combination had a slightly higher sensitivity of 94.4% for detecting long-segment BE (≥3 
cm) but still detected short segment BE of 1–3 cm length with 84.6% sensitivity. Although 
the study included only a few cases of dysplasia or cancer, the combination of mVIM and 
mCCNA1 did detect 9 of 11 dysplasias and 7 of 8 cancers, yielding sensitivity of 88% for 
detection of all BE, dysplasias, and cancers studied (Table 2). Overall, the encapsulated 
balloon device successfully sampled the distal esophagus with excellent tolerability and 
acceptability and, when combined with bisulfite sequencing for mVIM plus mCCNA1, 
demonstrated high sensitivity and specificity for detecting BE.
Methylation in other upper GI tract pathologies
To identify potential confounding sources of VIM and CCNA1 DNA methylation, we 
performed a retrospective analysis of archival formalin fixed paraffin embedded (FFPE) 
esophageal and gastric specimens that captured common pathologies of the upper GI tract 
(Table 3). As expected, FFPE biopsies of BE were highly methylated, with 90% testing 
positive for mVIM, 75% testing positive for mCCNA1, and 90% testing positive for the two 
marker panel. Clinical criteria for BE require identifying 1 cm or more of esophageal 
intestinal metaplasia (IM). However, the two marker panel additionally detected 80% of 
early esophageal intestinal metaplasias, identifying 80% of IM lesions <1 cm and still 
confined to the endoscopic GE junction (70% positive for mVIM and 67% positive for 
mCCNA1). Moreover, among individuals with BE, mVIM or mCCNA1 methylation could 
also be detected in 30% of biopsy samples of columnar mucosa that had no histologic IM 
(regions of gastric metaplasia) (Table 3), suggesting that the IM in these BE cases arose in 
an antecedent field of methylation-positive columnar cells. In contrast, among individuals 
without BE or IM, assays for mVIM and for mCCNA1 were negative in all GE junction 
Moinova et al. Page 7
Sci Transl Med. Author manuscript; available in PMC 2018 January 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
samples (n=55), whichincluded 15 cases with chronic carditis typified by columnar mucosa 
without IM (Table 3), and methylation was additionally negativein all distal esophagus 
samples (n=24).Together, these findings suggest that aberrant methylation occurs at the 
earliest stages of BE development, in those columnar mucosae that are actively evolving 
toward IM. Methylation is not simply a consequence of inflammation, because mVIM and 
mCCNA1 tests were all negative in each of 15 cases of eosinophilic esophagitis, as well as 
in the above-mentioned chronic carditis samples. Methylation was, however, additionally 
detected in a subset of gastric IM lesions, 22% of which were positive for at least 1 of the 
two markers. Moreover, 2 of 13 individuals with H. pylori gastritis, who were at increased 
risk for but did not have gastric IM, were also positive for VIM or CCNA1 methylation. 
However, 24 normal gastric fundic mucosa without IM were negative for mVIM in all 
samples and negative for mCCNA1 in all but one sample. Positive tests for mVIM and 
mCCNA1 are thus highly associated with IM, predominantly IM of the esophagus, but 
sometimes IM of the stomach.
Consistent with the predictions from this FFPE archive, positive methylation was detected 
on 2 of 3 balloon samples from cases of ultrashort BE (<1 cm), which were unevaluable in 
the primary analysis (2 positive for mVIM and none for mCCNA1). Similarly, positive 
methylation was detected in balloon samples from 4 of 4 cases of gastric intestinal 
metaplasia that were also unevaluable for the primary analysis (4 positive for mVIM and 2 
for mCCNA1). This finding of DNA methylation markers that are shared between gastric 
metaplasias and very early esophageal metaplasias is consistent with other genomic and cell 
biology lines of evidence that also point to a common origin between esophageal 
adenocarcinomas and intestinal type gastric cancers (19, 20)
VIM methylation was additionally identifiable in esophageal balloon samples from certain 
individuals in whom dysplastic BE had been previously ablated. Specifically, analysis of 
balloon samples from 23 endoscopically normal individuals who were unevaluable for the 
primary study, due to their having had ablation of prior dysplastic BE lesions, also 
demonstrated positive mVIM signals present in 8 (35%) patients (P < 0.017 for increased 
mVIM positivity in post-ablation versus evaluable control individuals) (table S8). This 
finding suggests that the endoscopically normal post-ablation GE junction, and/or post-
ablation neosquamous epithelium, may retain molecular abnormalities associated with prior 
IM and may hence harbor continued cellular precursors of BE. It will be intriguing to 
determine whether, on longitudinal follow-up, these individuals who retain VIM methylation 
after BE ablation will demonstrate a higher risk for BE recurrence. Curiously, only 2 of 
these 23 post-ablation individuals were positive for CCNA1 methylation.
Biological Implications
These studies in the esophagus help to inform the larger understanding of the genesis of 
aberrant DNA methylation in human neoplasias. Our data strongly point to epithelial cells as 
the source of both VIM and CCNA1 methylation signals. First, VIM and CCNA1 
methylation were both detected in epithelial fractions from microdissected FFPE samples of 
early and late BE lesions (Table 3). Second, EAC cell lines demonstrated nearly complete 
biallelic methylation (>97% of alleles methylated) in 5 of 5 cell lines for CCNA1 and in 4 of 
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5 cell lines for VIM (fig. S3). Third, testing in whole organ gastroesophagus porcine 
explants showed that the balloon device samples a nearly exclusively epithelial cell 
population (fig. S4). Consistent with this, no breaches of the surface epithelium (no 
abrasions) were detected in the human participants in this study, all of whom underwent 
upper endoscopic examination immediately after the balloon procedure. The basis for the 
aberrant methylation of VIM and CCNA1 genomic loci that we commonly found in BE-
related lesions remains obscure. As noted above, smoking was associated with increased 
mVIM and mCCNA1 only in the proximal (upper) but not in the distal esophagus (Fig. 4, 
table S5). Moreover, there is no clear functional implication of CCNA1 methylation in BE, 
because expression of this cyclin family gene is normally restricted primarily to the testis, 
with lesser expression in the brain, and because CCNA1 expression is not present in either 
unmethylated normal squamous esophagus or in methylated EAC cells (fig. S3). Similarly, 
VIM expression is also absent in the unmethylated normal esophagus (fig. S3). However, 
VIM expression is associated with epithelial to mesenchymal transition (EMT) of cancer 
cells (21), and although VIM expression was absent in all 4 VIM methylated EAC cell lines, 
VIM expression was detected in unmethylated FLO1 EAC cells (fig. S3), suggesting that 
VIM methylation may provide a mechanism for cancer cells to suppress EMT.
Discussion
This study demonstrates the feasibility of non-endoscopic office-based molecular cytology 
screening for BE and EAC. First, we have identified cytosine methylation of the CCNA1 
locus as a methylation marker of Barrett’s esophagus. Secondly, we have shown that 
molecular cytology assays of distal esophageal brushings, by bisulfite-sequencing detection 
of the 2-marker panel of mVIM and mCCNA1 DNAs, detects BE and EAC with sensitivity 
and specificity both greater than 90%. Thirdly, we have shown that a swallowable balloon 
device can obtain DNA samples from the distal esophagus in a rapid simple unsedated 
outpatient examination, and, when combined with bisulfite sequencing for detecting DNA 
methylation, maintains both sensitivity and specificity for detecting BE and EAC at close to 
90%. The combination of this sampling device and molecular diagnostic assay demonstrates 
the feasibility of non-endoscopic molecular cytology screening for BE as a method for 
ultimately preventing EAC development.
EAC has steadily increased in incidence over recent decades. With an 82% five year 
mortality rate, this cancer is the most rapidly increasing cause of cancer mortality from solid 
tumors in the American population (5). BE is a precursor lesion from which EAC develops, 
and ablation of BE with HGD and/or LGD is recommended to prevent EAC (22, 23). 
However, the great majority of EACs are diagnosed in patients who have never had prior BE 
screening. This reflects that most patients with GERD symptoms do not undergo upper 
endoscopy, and, moreover, that 40% of EACs develop in patients with no prior symptoms 
(24, 25). Thus, the success of ablation approaches in preventing EAC will remain limited 
without an acceptable and cost-effective method to effectively screen at-risk populations and 
detect those individuals who are harboring BE. Non-endoscopic balloon sampling paired 
with molecular assay for mVIM and mCCNA1 offers a technology to address this need for 
simple non-invasive BE screening.
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Given the need, other investigators have also advanced alternative approaches for BE 
screening. One such approach uses sponge-based devices for esophageal sampling (26, 27). 
One advantage of the balloon device is that it deploys rapidly by inflation, eliminating the 
waiting time for the coating on typical sponge devices to dissolve. Additionally, as the 
balloon retracts into its capsule after sampling, it enables directed sampling of the distal 
esophagus plus provides protection of the sample from dilution or contamination from the 
proximal esophagus or oral cavity. Moreover, the smaller dimensions of the retracted balloon 
provide for easier and more comfortable retrieval. Balloon sampling of the esophagus was 
first demonstrated by Falk and colleagues (28), with the current balloon based device now 
incorporating additional design enhancements that include optimized surface texturing and 
the addition of a protective capsule for delivery and retrieval.
Immunohistochemical detection of trefoil factor 3 has also been proposed as a biomarker for 
detection of BE, with a reported sensitivity of 79.9% when used with a cytosponge 
collection device (29). Attractions of DNA-based biomarkers include absence of subjectivity 
in interpretation and ease of automation for processing large sample numbers. Although 
direct comparison between the approaches will be of interest, the finding of 91% sensitivity 
for detecting BE metaplasia by mVIM plus mCCNA1 assays performed on balloon samples 
suggests this approach is likely at least as robust and may offer ease of examination and 
easier scalability to large populations. The lower background of CCNA1 methylation in 
control individuals sampled by esophageal balloons, as compared to cytology brushings, is 
intriguing, and perhaps reflects a useful advantage arising from the somewhat more 
superficial cell layer sampled by the balloon versus by cytology brushings.
We note that this study does have some limitations. This investigation was conducted at a 
single tertiary care institution, and establishing generality will require replication at other 
centers and in community-based populations. Our study population is also predominantly 
male Caucasians, suggesting caution in extrapolating these results to females and other 
ethnic groups, in which BE is less common. Additionally, we suffered failures of some 
participants to swallow the balloon device or of the device to obtain adequate sample. 
Remedying this limitation will need to be a focus of future enhancements to the device 
design. Last, we lack longitudinal follow-up to be able to interpret implications of finding 
positive tests for mVIM and mCCNA1 in endoscopically normal individuals without IM of 
stomach or esophagus or in higher risk individuals who are post ablation of dysplastic BE.
In summary, this study suggests that the combination of a balloon-based sampling device 
with bisulfite sequencing of the VIM and CCNA1 loci provides a highly sensitive and 
specific yet minimally invasive screening procedure that could be clinically useful for 
detection and screening of BE.
Materials and Methods
Study Design
The study protocol was approved by University Hospitals Case Medical Center and 
Cleveland Clinic Institutional Review Boards for Human Subject Investigation. Clinical trial 
registration numbers at ClinicalTrials.gov are NCT02451124 for the non-endoscopic balloon 
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trial and NCT00288119 for the endoscopic cytology brushings study. Subjects referred for 
outpatient EGD were approached for study participation. Consent for obtaining esophageal 
brushings and biopsies for research was obtained from subjects before their EGD. Cases 
were classified as subjects with newly diagnosed BE, those undergoing surveillance of BE, 
or those with a new diagnosis of esophageal or gastroesophageal junctional adenocarcinoma 
undergoing an endoscopic procedure. BE was defined according to current ACG guidelines 
as at least one cm of endoscopically visible columnar mucosa in the distal esophagus with 
intestinal metaplasia confirmed on histology (7). Lesions < 1 cm were classified as ultrashort 
BE and analyzed separately. Control subjects had no endoscopic evidence of BE and no 
histological evidence of intestinal metaplasia if a clinical biopsy was obtained from either 
the distal esophagus or gastroesophageal junction.
The overall study was a non-randomized observational study. Esophageal brushings were 
first used to validate findings from esophageal biopsies of methylated vimentin as a 
biomarker for detection of Barrett’s esophagus. Balloon-based esophageal samples were 
then obtained as a second validation sample. Study size was not pre-specified, and results 
are reported for esophageal brushing samples accrued from June 2011 to February of 2017 
and for all balloon samples accrued from July 2015 to August of 2016. No subjects were 
excluded from reporting. The primary endpoint of detection of Barrett’s esophagus and 
related progressed lesions was pre-specified before study initiation. All laboratory samples 
were assayed by investigators blinded to the clinical status of the subjects.
Reduced Representation Bisulfite Sequencing
Reduced representation bisulfite sequencing was performed as previously described (15). 
Genomic DNA isolated from frozen esophageal biopsies or cell lines was digested with 
MspI (New England Biolabs # R0106T). End repair, A-tailing, and adapter ligation were 
carried out using the NEXTFlex Bisulfite-sequencing library prep kit (Bioo Scientific, cat# 
NOVA-5119-02) with additional use of methylated NEXTFlex bisulfite-sequencing 
barcoded adapters (Bioo Scientific, cat# NOVA-511912) to allow for multiplexing multiple 
samples on a single sequencing lane. After adapter ligation, the library was size fractionated 
on an agarose gel, and DNA fragments between 170–350 bps (corresponding to the initial 
unligated 40–220 bp MspI digest fragments) were isolated and purified from the gel using 
Macherey-Nagel gel extraction and PCR purification kit (Cat#740609.250). After elution 
from the columns, DNA was bisulfite converted using the EpiTect Bisulfite Conversion Kit 
(QIAGEN, cat# 59104). Adapter-ligated and converted libraries were then PCR amplified 
and purified using Macherey-Nagel gel extraction and PCR purification kit.
Sequencing was performed on an Illumina HiSeq 2500 using paired-end 100 bp reads. 
Individual BAM files for each sample were generated for alignment. DNA sequencing reads 
from each RRBS experiment were aligned to bisulfite-converted and unconverted versions of 
the human reference genome (hg18) using Bowtie2, and percent methylation for each CpG 
was calculated by dividing the number of methylated Cs by the total coverage of that base. 
These analyses were facilitated by the Bismark software (32), which was specifically 
developed for processing RRBS data. The overall pipeline converts raw RRBS fastq files to 
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tables of read depth and percent methylation at each individual CpG site for each patient 
sample.
Endoscopic Sampling
During the endoscopy, one cytology brushing (US Endoscopy) was obtained from the 
proximal squamous esophagus, 20–25 cm from the incisors, as soon as the esophagus was 
intubated. The second cytology brushing was obtained from endoscopic BE or cancer 
lesions. In endoscopic normal controls, the gastroesophageal junction was brushed to sample 
the glandular mucosa as well as distal squamous mucosa. Standard of care clinical biopsies 
were obtained from suspected BE and cancer cases. Data were collected from subjects 
regarding demographics, indications for EGD, GERD symptoms, exposures, and past 
medical history. All diagnoses (Table 1) were established by endoscopic report and 
histopathology review of clinical biopsy samples. Demographic data for all patients are 
provided in table S2. Brushes were immediately clipped with wire cutters into empty 
nuclease-free 0.5 ml cryo-safe tubes and immediately snap frozen on dry ice for transport to 
storage at −80°C until use. Genomic DNA was extracted from endoscopic brushes using the 
DNeasy blood and tissue kit (Qiagen #69504). The protocol for the purification of Total 
DNA from Animal Tissues (Spin-Column Protocol) was used with the modification of 
increasing the digestion time to overnight. Final elution volume was 100 µl. DNA yields 
from clinical samples were quantitated using the Qubit fluorometer (Invitrogen).
FFPE Tissues Specimens
Archival normal and neoplastic tissue specimens were obtained from the Department of 
Pathology at University Hospitals Case Medical Center under a tissue procurement protocol 
approved by University Hospitals Case Medical Center Institutional Review Board. Before 
use, diagnostic slides of all samples were reviewed by a gastrointestinal pathologist (J.W.) 
for confirmation of the recorded diagnoses. After confirmation of diagnoses, specimens for 
this study were prepared via punch biopsies of tissue blocks. The presence of intestinal 
metaplasia in designated esophageal biopsies was required for a diagnosis of Barrett’s 
esophagus according to published guidelines.(7)
DNA was purified using QIAamp DNA micro kit (QIAGEN) according to the 
manufacturer’s protocol with the following modifications: The starting extraction volume 
was increased to 200 µl ATL buffer and 50 µl proteinase K. The cores were digested for four 
days at 60 degrees. An additional 6 µl of Proteinase K was added on days 2 and 3 of 
incubation. The DNA was eluted from columns in 100 µl of low-TE elution buffer and used 
immediately for bisulfite conversion, or frozen at −80°C until use.
Non-endoscopic esophageal brushing via a balloon device
We designed an encapsulated, inflatable, surface-featured balloon for targeted sampling of 
the distal esophagus. The device was delivered in a 16 by 9 mm capsule that also protected 
the acquired biospecimen from potential contamination with proximal esophagus material 
during withdrawal. Subjects referred for outpatient EGD were approached for study 
participation. Patients underwent un-sedated distal esophageal sampling with the balloon 
device before scheduled EGD. After a patient swallowed the capsule with the balloon and 
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the capsule was allowed to reach the stomach, the balloon was inflated with 5–5.5 cc of air 
using the attached tubing and syringe. On average, the balloon reached the stomach in 3:21 
minutes (range, 1 to 7:39 minutes). The inflated balloon was pulled slowly for 3–6 cm from 
the point where the constriction of the esophageal sphincter was felt by the endoscopist, and 
then deflated using an attached syringe, thus retracting the balloon inside the capsule and 
protecting the sample. After the capsule was removed, the balloon was re-inflated, cut off 
from the capsule, and immediately frozen. DNA was extracted from balloons using the same 
protocol as for endoscopic brushings, but with the modification of increasing the volumes of 
kit buffers ATL and AL to 1 ml, in order to completely cover the balloons. After the 
procedure, each patient filled out a standardized tolerance and acceptance questionnaire 
(table S9) (30).
Bisulfite conversion of the genomic DNA
To create a template for PCR and then DNA methylation analysis, DNA samples were 
subjected to treatment with sodium bisulfite, which converts unmethylated cytosine bases 
into uracil, while leaving methylated cytosines intact, using an Epitect kit (QIAGEN) 
according to the manufacturer’s protocol. The person performing the methylation analysis 
was blinded to the clinical history of the samples until after all procedures and calculations 
were completed.
Bisulfite-Sequencing-based methylation detection (Bisulfite-Seq
Bisulfite-converted DNA samples from cytology brushings were analyzed by NGS. 
Bisulfite-specific, methylation-indifferent PCR primers were constructed as a mixture of 
primers against converted products of fully methylated or fully unmethylated templates and 
were used to amplify a differentially-methylated region of the vimentin exon 1 CpG island 
(previously described, (31)) or CCNA1 (table S10). Platinum Taq reaction mix (Invitrogen) 
was supplemented with 1 mM MgCl2, 0.2 mM dNTP mix (New England Biolabs), 0.5 M 
Betaine (Sigma), and a mix of the 4 primers, each at 0.1 µM final concentration. PCR was 
performed using a touchdown protocol where after the activation of Taq polymerase at 95°C 
for 5 min, the initial cycling conditions were: 95°C for 45 sec, 67°C for 45 sec, 72°C for 45 
sec. The annealing temperature was decreased by 3°C every 3 cycles, to a final of 55°C. An 
additional 33 cycles of PCR were performed at the annealing temperature of 55°C. 
Successful amplification was confirmed by agarose gel electrophoresis. PCR products were 
purified using NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel), and quantitated by 
Qubit. The NEXTflex Rapid DNA-seq kit (BIOO Scientific) was used to prepare indexed 
libraries for NGS sequencing (Illumina-compatible), and NGS was performed using a 
MiSeq platform at the McGill University and Génome Québec Innovation Centre, Montréal, 
Canada. FFPE DNA samples were bisulfite-converted and sequenced by Epiquest (Zymo 
Research), using the same protocol as above.
Analysis of non-endoscopic balloon DNA samples was done the same way as for brushing 
samples above, except that the PCR amplification primers (table S10) were indexed by 
adding 96 different 7 bp index tags to the 5’ end of both forward and reverse primers (table 
S11). The amplification with indexed primers was carried out under the same conditions as 
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for non-indexed primers, and the PCR products were subsequently mixed together, before 
preparing a library for NGS using a non-indexed library adapter.
DNA sequencing reads from each sample were aligned to bisulfite converted and 
unconverted versions of the human reference genome (hg18) using Bowtie2. VIM aligned 
reads were classified as methylated if they indicated that 8 or more CpG dinucleotides were 
methylated (out of total of 10 CpGs present between the primers in the VIM PCR fragment). 
CCNA1 aligned reads were classified as methylated if they indicated that 16 or more CpG 
dinucleotides were methylated (out of total of 21 CpGs present between the primers in the 
CCNA1 PCR fragment). These analyses were facilitated by use of Bismark software (32), 
which was specifically developed for processing bisulfite-sequencing data.
Statistical methods
Between-group comparisons of continuous variables were performed using unpaired t test 
(for two groups) or one-way ANOVA for groups of 3 or more, followed by the post-hoc 
Student-Newman-Keuls test for all pairwise comparisons. The Mann-Whitney rank sum test 
was used to determine the p-value for comparison of smokers and non-smokers. Fisher’s 
exact test was used for comparison of demographic composition of cases/controls in 
brushing and balloon studies. ROC curves, and all associated statistics were generated using 
MedCalc software. The optimal cut-points were calculated as maximizing the sum of 
sensitivity plus specificity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CCNA1 region methylation in esophageal neoplasia
(A) Location of the differentially methylated region in the CCNA1 promoter on 
chromosome 13. The patch of CpGs found to be differentially methylated in reduced 
representation bisulfite sequencing (RRBS) and the amplicon assayed by next-generation 
sequencing are indicated above the map of the CpG island (green), with structures of 
CCNA1 RefSeq transcripts indicated below. (B) Average methylation of CpGs in the 
CCNA1 RRBS-defined patch of 7 CpGs in: biopsies of normal squamous mucosa (N Sq), 
Barrett’s esophagus (BE), esophageal adenocarcinoma (EAC), and in esophageal cell lines 
(CL).
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Figure 2. NGS bisulfite sequencing assay of DNA methylation in esophageal biopsies
(A) CCNA1 locus methylation (mCCNA1) in esophageal neoplasia and control patients. N 
Sq (normal squamous biopsies); NDBE (non-dysplastic Barrett’s esophagus); HGD 
(Barrett’s esophagus with high-grade dysplasia); EAC (esophageal adenocarcinoma). 
Fraction of methylated reads in each sample is indicated on the Y-axis. P-value <0.001 for 
one way ANOVA comparison, and p<0.001 for post-hoc Student-Newman-Keuls test of N 
Sq versus BE, HGD, and EAC.
(B) VIM locus methylation (mVIM) in esophageal neoplasia and control patients. N Sq 
(normal squamous biopsies); NDBE (non-dysplastic Barrett’s esophagus); HGD (Barrett’s 
esophagus with high-grade dysplasia); EAC (esophageal adenocarcinoma). Fraction of 
methylated reads in each sample is indicated on the Y-axis. P-value <0.001 for one way 
ANOVA comparison, and p<0.001 for post-hoc Student-Newman-Keuls test of N Sq vs BE, 
HGD, and EAC.
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Figure 3. ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from 
control normal-appearing GE junctions versus BE and EAC cases
(A) and (B) Training samples. (A) mCCNA1, n= 61 controls, 108 cases. (B) mVIM, n= 59 
controls and 107 cases. (C) and (D) Validation samples. (C) mCCNA1, n= 28 controls, 115 
cases. (D) mVIM, n= 27 controls and 117 cases. Area under the curve (AUC) and the 
sensitivity and specificity of the assays at the indicated cutpoint are listed for each graph, 
with the cutpoint value of percent methylation that defines a positive test denoted by “At >”.
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Figure 4. DNA methylation in the proximal squamous esophagus of smokers versus non-smokers
(A) mCCNA1, *p=0.0094; (B) mVIM, *p=0.0155. Patients were classified as smokers if 
they had any history of ever smoking. P values for differences between smokers and non-
smokers were computed using the Mann-Whitney rank sum test.
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Figure 5. Non-endoscopic balloon device
(A) Device capsule and catheter in comparison to a vitamin pill and a dime. (B) Capsule 
containing inverted balloon in configuration for swallowing. (C) Capsule with inflated 
balloon in configuration for esophageal sampling. (D) Capsule containing inverted balloon 
in configuration for device and biospecimen retrieval.
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Figure 6. ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the 
distal esophagus
(A) mCCNA1, n=36 controls, 50 cases. (B) mVIM, n=36 controls, 50 cases. Area under the 
curve (AUC), and the sensitivity and specificity of the assays at the indicated cutpoints are 
listed for each graph, with the cutpoint value of percent methylation that defines a positive 
test denoted by “At >”.
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